Long-Term Outcomes of Children With Congenital CMV in New York State

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age0-1
SponsorStony Brook University

About this trial

PROACTIVE NYS is a long-term follow-up study of all infants who test positive for congenital Cytomegalovirus infection (CMV) throughout New York State on the Newborn Screen. By following all infants who screen positive, we will learn important information about the range of symptoms caused by congenital CMV, from those babies with more severe findings to those with no symptoms.

In particular, our study will provide new information about many facets of congenital CMV, including:

* Developmental, hearing, neurologic, and vision outcomes * The spectrum and timing of symptoms * The impact congenital CMV has on the baby and its family * How many babies are infected with congenital CMV in New York State How antiviral medications and other interventions impact outcomes of children with congenital CMV

Throughout the duration of the study, children will undergo routine developmental and hearing assessments, which will assist with early diagnosis of any infection complications.

Any child found to have a neurodevelopmental, hearing, or vision abnormality will be referred for appropriate evaluation and treatment.

Families will also be asked to complete periodic surveys about their experience with congenital CMV, both as a medical diagnosis and as it affects their day-to-day activities.

Eligibility criteria

Qualifiers

Neonates born in New York State during cCMV NBS Pilot Program (September 27, 2023 - October 1, 2024)

cCMV evaluation provided by a designated NYS cCMV clinical referral site

Family willing and able to complete all study procedures

1. Category 1 (Confirmed cCMV identified by NBS Program): cCMV NYS newborn screen positive AND cCMV confirmatory test positive

Disqualifiers

Neonate whose parents refuse participation in the long-term follow-up study

Trial design

Treatments tested in this trial

  • Not listed

Trial groups

1,000 Participants
are grouped into 4 trial groups

Sponsors and collaborators

Stony Brook University

Lead sponsor

Frontier Science & Technology Research Foundation, Inc.

Collaborator